Table 1.
Patient characteristics (sites of metastasis, disease response, and duration of survival).
| Patient | No. of brain lesions at diagnosis of brain metastases | Extracranial sites of metastasis | Intracranial response | Extracranial response | Global response | Duration of survival from HD IL-2 initiation (months) |
Duration of survival from diagnosis of brain metastases (months) |
|---|---|---|---|---|---|---|---|
| 1 | 2 | Subcutaneous lesions | Undocumented progression | Progression | Progression | 6.7 | 7.4 |
| 2 | 1 | None at start of HD IL-2 (small bowel mets s/p resection) |
Progression | n/a | Progression | 10.6 | 13.5 |
| 3 | 1 | Lungs | n/a (complete radiosurgical response of solitary brain met) |
Partial response (residual lung lesions resected) |
Surgical complete response | 19.0 | 23.7 |
| 4 | 3 | Muscles, retrocrural soft tissue | Progression | Stable disease | Progression | 13.3 | 15.2 |
| 5 | 3 | Pulmonary soft tissue, LNs, liver, kidney, prostate, and bones | Progression | Mixed response | Progression | 18.2 | 19.6 |
| 6 | 15–20 | Lung (multiple), paraspinal muscles | Partial response | Mixed response | Progression | 5.3 | 5.4 |
| 7 | 1 | Lung (multiple), mediastinum, soft tissue, kidney, spleen, LNs, and bones |
Undocumented progression | Progression | Progression | 2.1 | 5.1 |
| 8 | 7 | Hilum, lungs, pulm. soft tissue, and adrenal glands | Progression | Progression | Progression | 3.0 | 4.7 |